Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis
Author(s)
Tummala, Ramyashree
Gupta, Manasvi
Devanabanda, Arvind Reddy
Bandyopadhyay, Dhrubajyoti
Aronow, Wilbert S
Type
Journal Article
Abstract
Atherosclerotic heart disease is the leading cause of mortality and morbidity in the USA. Low density lipoprotein (LDL) has been the target for many hypolipidemic agents to modify atherosclerotic risk. Bempedoic acid is a novel hypolipidemic drug that inhibits the enzymatic activity of ATP citrate lyase in the cholesterol synthesis pathway. CLEAR Harmony, CLEAR Wisdom, CLEAR Tranquillity and CLEAR Serenity have shown safety and efficacy associated with long term administration of this drug. Studies have shown effectiveness in reducing LDL-C in both statin intolerant patients and in patients on maximally tolerated doses of statin. The fixed drug combination of bempedoic acid and ezetimibe in a recent phase III showed significant reduction in LDL compared with placebo, which might be a promising future for LDL reduction among statin intolerant patients. Bempedoic acid also reduced inflammatory markers like hs-CRP. Given these results, bempedoic acid alone and in combination with ezetimibe received the USA FDA approval for adults with heterozygous familial hypercholesterolaemia or established atherosclerotic cardiovascular disease. We present a comprehensive review exploring the underlying mechanism, pre-clinical studies, and clinical trials of bempedoic acid and discuss the potential future role of the drug in treating hyperlipidaemia.
Date Issued
2022-12-01
Date Acceptance
2022-03-24
Citation
Annals of Medicine, 2022, 54 (1), pp.1287-1296
ISSN
0785-3890
Publisher
Taylor & Francis Group
Start Page
1287
End Page
1296
Journal / Book Title
Annals of Medicine
Volume
54
Issue
1
Copyright Statement
© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
License URL
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000792515200001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Subjects
atherosclerosis
ATP-CITRATE LYASE
Bempedoic acid
CLEAR HARMONY
CLEAR OUTCOMES
CLEAR WISDOM
DENSITY-LIPOPROTEIN-CHOLESTEROL
EFFICACY
ETC-1002
General & Internal Medicine
HEART-DISEASE
HYPERCHOLESTEROLEMIA
INFLAMMATION
LDL-C
Life Sciences & Biomedicine
Medicine, General & Internal
PCSK9 INHIBITORS
SAFETY
Science & Technology
Publication Status
Published
Coverage Spatial
England
Date Publish Online
2022-05-09